Literature DB >> 10654024

A case of hemolytic uremic syndrome improved with nitric oxide.

T Kajiume1, A Nagita, S Yoshimi, K Kobayashi, N Kataoka.   

Abstract

Hemolytic uremic syndrome (HUS) after transplantation is difficult to treat, and there is no consensus regarding optimal mode of treatment. We attached transdermal isosorbide tape as a nitric oxide (NO) donor to patients with HUS after bone marrow transplantation (BMT). This was very effective in ameliorating the hemolysis and increasing platelet numbers. We report here the successful use of an isosorbide in a patient with HUS after transplantation. Bone Marrow Transplantation (2000) 25, 109-110.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10654024     DOI： 10.1038/sj.bmt.1702098

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

2.  Rapid Improvement in Jaundice Using Transdermal Isosorbide Tape as a Nitric Oxide Donor in Two Adult Patients with Transplantation-associated Microangiopathy Related to Graft-versus-host Disease.

Authors:  Yuki Hiroshima; Keijiro Sato; Toshimitsu Ueki; Masahiko Sumi; Mayumi Ueno; Naoaki Ichikawa; Hidetoshi Satomi; Hikaru Kobayashi
Journal:  Intern Med       Date:  2021-09-25       Impact factor: 1.282

3.  L-arginine/NO pathway is altered in children with haemolytic-uraemic syndrome (HUS).

Authors:  Nele Kirsten Kanzelmeyer; Lars Pape; Kristine Chobanyan-Jürgens; Dimitrios Tsikas; Hans Hartmann; Anne-Jule Fuchs; Bernhard Vaske; Anibh Martin Das; Marion Haubitz; Jens Jordan; Thomas Lücke
Journal:  Oxid Med Cell Longev       Date:  2014-03-17       Impact factor: 6.543
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.